Allworth Financial LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,334 shares of the medical research company's stock, valued at approximately $12,200,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $7,505,000. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. Hudson Value Partners LLC boosted its holdings in Thermo Fisher Scientific by 24.9% in the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after purchasing an additional 3,317 shares during the period. Xponance LLC grew its position in Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock worth $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Annex Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 12.6% in the 2nd quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company's stock worth $12,361,000 after acquiring an additional 2,756 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have weighed in on TMO shares. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Piper Sandler increased their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. Finally, Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $619.41.
Get Our Latest Analysis on Thermo Fisher Scientific
Insider Activity
In other news, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 63,493 shares of company stock worth $37,657,681. Corporate insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO opened at $629.02 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a 50 day moving average price of $542.53 and a 200 day moving average price of $509.70. The stock has a market capitalization of $232.58 billion, a PE ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter last year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
